

## ORIGINAL RESEARCH

*Chlamydia trachomatis*, *Neisseria gonorrhoeae* and human papillomavirus infections of lower genital tract of Indigenous women from Xingu Indigenous Park

## AUTHORS



Claudia Regina Cinti Correa Porto<sup>1</sup> PhD, Postdoctoral Fellow



Adhemar Longatto-Filho<sup>2</sup> PhD, Associate Professor



Bruna Cristine De Almeida<sup>3</sup> PhD, Postdoctoral Fellow



Tatiana CS Bonetti<sup>4</sup> PhD, Affiliated Researcher Professor



Sula Fernanda A Kamaiurá<sup>5</sup> Vice-President of the Yamurikumã Association



Ricardo Sobhie Diaz<sup>6</sup> MD, PhD, Associate Professor



Thais Heinke<sup>7</sup> MD, PhD, Adjunct Professor



Fernanda de Paula Cury<sup>8</sup> MSc, Laboratory Technician



Iara Viana Vidigal Santana<sup>9</sup> MD, Pathologist



Mariana M Queiroz<sup>10</sup> Nurse, Coordinator of Women's Health at the Xingu Project



Douglas Antonio Rodrigues<sup>11</sup> MD, PhD, Coordinator of the Indigenous Clinic



Neila Maria De Gois Speck<sup>12</sup> MD, PhD, Adjunct Professor \*

## CORRESPONDENCE

\*Adj Prof Neila Maria De Gois Speck nezespeck@uol.com.br

## AFFILIATIONS

<sup>1, 12</sup> Gynecological Disease Prevention Nucleus (NUPREV), Department of Gynecology, Paulista Medical School (UNIFESP/EPM), Federal University of São Paulo, 821 Botucatu Street, São Paulo, SP 04023-062, Brazil

<sup>2</sup> Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; School of Medicine, Life and Health Sciences Research Institute, ICVS/3B's - PT Government Associate Laboratory, Campus de Gualtar, University of Minho, Braga 4710-057, Portugal; and Laboratory of Medical Investigation (LIM) 14, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, HCFMUSP, 455 Dr. Arnaldo Avenue, São Paulo, SP 05403-010, Brazil

<sup>3</sup> Structural and Molecular Gynecology Laboratory (LIM 58), Discipline of Gynecology, Department of Obstetrics and Gynecology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, HCFMUSP, 455 Dr. Arnaldo Avenue, São Paulo, SP 05403-010, Brazil

<sup>4</sup> Molecular Gynecology Laboratory, Department of Gynecology, Paulista Medical School (UNIFESP/EPM), Federal University of São Paulo, 781 Pedro de Toledo Street, São Paulo, SP 04039-032, Brazil; and Professor Geraldo Rodrigues de Lima Neuroscience Center and Women's Health, Department of Gynecology, Federal University of São Paulo – Paulista Medical School (UNIFESP/EPM), São Paulo, SP, Brazil

<sup>5</sup> Yamurikumã Association, 733 Paraná Avenue, Nova Canarana, Canarana, Mato Grosso, 78640-000, Brazil

<sup>6</sup> Department of Infectious Diseases, Paulista Medical School (UNIFESP/EPM), Federal University of São Paulo, 669 Pedro de Toledo Street, São Paulo, SP 04039-032, Brazil

<sup>7</sup> Department of Pathology, Paulista Medical School (UNIFESP/EPM), Federal University of São Paulo, 740 Botucatu Street, São Paulo, SP 04023-062, Brazil

<sup>8,9</sup> Pathology Department of Fundação Pio XII / Barretos Cancer Hospital, 1331 Antenor Duarte Vilela Street, Pavilhão João Paulo e Daniel, Barretos, SP 14784-400, Brazil

<sup>10,11</sup> Department of Preventive Medicine, Paulista Medical School (UNIFESP/EPM), Federal University of São Paulo, 740 Botucatu Street, São Paulo, SP 04023-062, Brazil

## PUBLISHED

29 July 2023 Volume 23 Issue 3

## HISTORY

RECEIVED: 27 August 2021

REVISED: 22 October 2022

ACCEPTED: 4 March 2023

## CITATION

Correa Porto CR, Longatto-Filho A, De Almeida BC, Bonetti TC, Kamaiurá SA, Diaz RS, Heinke T, Cury FD, Santana IV, Queiroz MM, Rodrigues DA, De Gois Speck NM. *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and human papillomavirus infections of lower genital tract of Indigenous women from Xingu Indigenous Park. *Rural and Remote Health* 2023; 23: 7126. <https://doi.org/10.22605/RRH7126>

This work is licensed under a [Creative Commons Attribution 4.0 International Licence](https://creativecommons.org/licenses/by/4.0/)

## ABSTRACT:

**Introduction:** Xingu Indigenous Park (XIP) currently protects 16 ethnic Indigenous groups and is located in the central area of Brazil. XIP is the first and the largest Indigenous land to be recognized in the country. Community access is limited and restricted for the non-Indigenous population, and the Indigenous women are constantly dealing with shortages of medical care. High-risk human papillomavirus (HR-HPV) is the most common cause of cervical cancer and is detected in 99% of cervical precancers. HPV infections may be associated with bacterial agents such as *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, which are also important causative agents of sexually transmitted infections and are responsible for the most frequent bacterial infections in the world. The present study evaluated the frequency and potential impact of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and HR-HPV in the Indigenous women of XIP.

**Methods:** In this cross-sectional study, 992 cervical–vaginal samples were collected from Indigenous women, using a Cervex-Brush, and were immediately placed in a SurePath medium. All samples were submitted to the cobas® 4800 detection system for the identification of 14 different types of HR-HPV, and the

**Keywords:**

Brazil, *Chlamydia trachomatis*, HR-HPV, Indigenous women, *Neisseria gonorrhoeae*, sexually transmitted infections, Xingu Indigenous

multiplex Abbott RealTime CT/NG assay for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.

**Results:** HR-HPV was detected in 18.2% of women; 6% were positive for HPV16, 5% for HPV18, and 81% for other types of HR-HPV. Co-infections of HPV16 and other types was observed in 5% of women, and 3% had co-infections of HPV18 and other types. Moreover, 1.8% of women were positive for *Chlamydia trachomatis*, while *Neisseria gonorrhoeae* was not detected. In women with HR-HPV, 33% had *Chlamydia trachomatis* infections, 28% were positive for HR-HPV other than HPV16 or HPV18, and 5% had co-infections of HPV16 and the other types of HPV. Younger women were found to be more susceptible to HPV infections.

**Conclusion:** The findings indicate a high frequency of HR-HPV and a considerable frequency of *Chlamydia trachomatis* in the Indigenous women of XIP. The detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and/or HR-HPV does not present evidence of a potential interrelationship for a combined pathogenic action in these women.

## FULL ARTICLE:

### Introduction

The Indigenous population of Brazil comprises 817 963 people, corresponding to 0.4283% of the total Brazilian population. According to the latest demographic survey conducted in 2010, Indigenous people are distributed in both rural and urban areas of the country<sup>1,2</sup>. Xingu Indigenous Park (XIP) was created in 1961 to protect the physical and cultural aspects of the Indigenous peoples who live there, guaranteeing environmental preservation and sheltering Indigenous groups threatened with extinction. It is the first and the largest Indigenous land to be recognized in the country, protecting 16 ethnic groups. XIP is located in the central area of Brazil, south of the Amazon and north-east of Mato Grosso state. According to the Indigenous Health Information System, in 2013, the Indigenous population of XIP totaled 6589 inhabitants distributed in four regions: Upper, Middle, Lower, and East Xingu<sup>2</sup>.

In recent decades, the exposure of this population to different infectious agents has increased, as has contact with non-Indigenous people living in the vicinity, and the opening of new roads. Indigenous women are more exposed to risk cofactors for the development of cervical cancer, such as early sexual activity, multiple sexual partners, the non-use of condoms, and multiparity; additionally, it is common for Indigenous women to spend approximately 30 years in a prolonged reproductive period<sup>3</sup>. The Indigenous population is constantly dealing with shortages of medical care owing to restricted and limited access for outsiders to the Indigenous area. Organized activities such as STI screenings, prenatal care, and laboratory tests are not available<sup>4</sup>. Moreover, when treatment of Indigenous women does occur, a syndromic approach is taken owing to the lack of laboratory testing for STIs, as recommended by the Brazilian Ministry of Health<sup>5</sup>.

There is a high rate of cervical cancer among Indigenous women worldwide<sup>6</sup>. Oncogenic types of high-risk human papillomavirus (HR-HPV) are responsible for 99% of cervical cancers, which is the second most common cancer in underdeveloped countries<sup>7,8</sup>. HR-HPV16 and 18 are responsible for approximately 70% of cervical cancers<sup>9,10</sup>. Persistent HPV infections in women are also associated with genital warts, as well as vulva and vaginal cancers<sup>9,11</sup>.

Other STIs, such as *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG), are the major causes of pelvic inflammatory disease and infertility in women<sup>12</sup>. CT and HPV have the same sexual transmission pathway with similar risk factors, indicating that a co-infection can act synergistically in the induction of cellular atypia<sup>13</sup>.

CT is responsible for the most frequent bacterial infections in the world, followed by NG, according to the WHO<sup>14,15</sup>. CT is commonly found in sexually active young people<sup>14</sup>, and in untreated women it can lead to pelvic inflammatory disease, fallopian tube complaints, infertility, chronic pelvic pain, and ectopic pregnancy<sup>16,17</sup>. Studies have demonstrated that the placenta and amniotic fluid can become infected, indicating a strong association with premature births and miscarriage<sup>18</sup>. A co-infection of CT and NG can also bring on these symptoms and disorders<sup>19</sup>. Furthermore, gonococcal infection has progressively developed resistance to the antibiotics that have been increasingly used in recent years, thus reducing the options for treatment.

Asymptomatic cases of gonococcal infection are very common and can result in a fivefold increase in HIV transmission<sup>20,21</sup>.

The notification rates of CT and NG infections in Indigenous people in Australia have increased by 80% and 22%, respectively. The highest notification rates were in infections in Indigenous women aged 15–19 years, and those living in remote areas<sup>22</sup>. However, to the best of our knowledge, no previous studies have described the epidemiology, clinical features, and management related to STIs caused by CT and NG in Indigenous women from XIP. An investigation of these infections, together with the detection of the presence, and viral type, of HPV can significantly contribute to the understanding and control of STIs in the Indigenous population. Therefore, the present study aims to evaluate the lower genital tract infections caused by CT, NG, and HPV in the Indigenous women of XIP.

Since 2005, the Federal University of São Paulo – Paulista Medical School (UNIFESP-EPM), including a group of professionals from the Health and Environment Unit of the Department of Preventive Medicine/Xingu Project, and the Prevention of Gynecological Diseases Center (NUPREV) of the Department of Gynecology, has been working on the prevention, diagnosis, and treatment of diseases of the lower genital tract of sexually active women from XIP. The implementation of this cervical cancer prevention program has resulted in a reduction in the number of abnormal pap smears, showing that the strategies have been effective in controlling cervical intraepithelial neoplasia. This type of special attention offered by the university to this Indigenous population is unusual in Brazil. Indigenous communities must usually rely on unstable or absent financial resources or non-governmental organizations.

### Methods

This cross-sectional study included 992 Indigenous women living in the Upper, Middle, Lower, and East Xingu regions of XIP who met the inclusion criteria: participants must have had or currently have sexual partners and must be aged more than 18 years. Pregnant women of any gestational age were excluded from the study.

### Collecting and preserving the samples

The collection of cervical smear samples from the women was organized in two phases in 2018 owing to the difficulties accessing these areas. The first samples, collected in the first phase, were from women from Upper Xingu ( $n=499$ ) and the second phase collection was from women from Lower, Middle, and East Xingu ( $n=493$ ). The collections were carried out in health centers, schools, empty houses, or isolated areas according to the structure or availability of the community. The workflow diagram of the study is shown in Figure 1.

Patients were kept in a gynecological position, the Collins speculum was introduced vaginally, and, after exposure to the cervix, the cellular material was collected with a Rovers® Cervex-Brush® (<https://www.roversmedicaldevices.com>), which was used as suggested by the manufacturer. A SurePath liquid medium (<https://www.bd.com/en-us/products-and-solutions/products>

/product-brands/surepath) was employed for sample storage and preservation.

For data analysis and to verify the infection index of CT and HPV, we defined the cut-off age as 25 years, maintaining an age balance between the CT screening guidelines (less than 24 years according to the Centers for Disease Control and Prevention and more than 25 years for cervical cancer screening according to the Brazilian Guidelines for the Control of Cervical Cancer<sup>5,23</sup>).

#### Cobas® 4800 for HPV test

HPV genotyping tests were performed at the Hospital de Amor pathology service, using the Roche cobas 4800 detection system (Roche, Branchburg, New Jersey, US). The cobas 4800 identified 14 types of HR-HPV in a single analysis, including the individual detection of HPV16 and HPV18, and the simultaneous detection of 12 HR-HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that form a single group named 'other types' at clinically relevant levels of infection<sup>24</sup>. All protocols were performed according to the manufacturer's instructions. Subsequently, all samples were carefully analyzed. To better describe the results, subjects were divided into three groups based on cobas 4800 genotyping data: an HPV16 group; an HPV18 group; and an 'other types' group that included women with an amplification of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68.

#### Abbott RealTime CT/NG

The detection of CT and NG was performed at the retrovirology laboratory in the infectious diseases discipline at UNIFESP-EPM. All samples were tested with the Abbott RealTime CT/NG assay


(Abbott Laboratories, Illinois, US), which used quantitative reverse transcription (qRT)-PCR detection for the pair CT and NG<sup>25-27</sup>. The assay consisted of two reagent kits: the Abbott RealTime CT/NG amplification reagent kit and the Abbott RealTime CT/NG control kit. DNA was extracted from each specimen using the Abbott *m2000sp* automated system, and qRT-PCR detection was performed with the Abbott *m2000rt* instrument for amplification and detection according to the manufacturer's instructions. A negative control and two replicate samples of the cut-off control were used for each process. This system is a qualitative assay and the data were interpreted as previously described<sup>28</sup>.

#### Statistical analysis

The age of the women is presented by mean and standard deviation (mean±SD). For qualitative comparisons, Pearson's  $\chi^2$  test or Fisher's exact test was used to analyze the differences among the frequencies of each variable. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, California, US) and Statistical Package for Social Sciences v21 (IBM Corp.; <https://www.ibm.com/products/spss-statistics>). Statistical significance was set at  $p \leq 0.05$ .

#### Ethics approval

The present study was approved by the Ethics and Research Committee of UNIFESP-EPM under protocol number CEP 1753/06 and the National Research Ethics Commission under protocol number 14320, and was conducted in accordance with the ethical standards of the Declaration of Helsinki. Prior to the study, all patients agreed with and signed an informed consent form.



CT, *Chlamydia trachomatis*; HPV, human papillomavirus; NG, *Neisseria gonorrhoeae*; XIP, Xingu Indigenous Park.

Figure 1: A flow diagram of the study design with details of the number of participants and diagnostic method used.

#### Results

The Indigenous women had an average age of  $33.2 \pm 12.0$  years, ranging from 18 to 75 years. In total, 992 samples were tested for HPV, of which 23 remained inconclusive and 18.2% (177 of 969) were positive for some kind of HR-HPV. The presence or absence of HPV (positive or negative) was also evaluated and distributed by

age. Of the women aged  $\leq 25$  years ( $n=317$ ), 26.8% ( $n=85$ ) were positive and 73.2% ( $n=232$ ) were negative for HPV. Of the women aged  $\geq 26$  years ( $n=652$ ), 14.1% ( $n=92$ ) were positive and 85.9% ( $n=560$ ) were negative for HPV ( $p \leq 0.0001$ ). It was observed that women aged less than 25 years had a higher frequency of HPV infection than older women proportionally (Table 1).

Furthermore, among HPV-positive women, 48% (85) were  $\leq 25$  years and 52% (92) were  $\geq 26$  years. The HR-HPV other-types group was most frequently found in women aged  $\leq 25$  years (72 women; 22.7%), while for those aged  $\geq 26$  years, 11.2% (73) of women were positive for this viral group ( $p \leq 0.0001$ ).

Comparing the distribution frequency between HPV16, HPV18, and the other-types group, women infected with the other-types group were the majority (145 of 177 women; 81%). Only 6% (11) of women had HPV16 exclusively and 5% (8) had HPV18 exclusively. Co-infection of HPV16 and the other types was found in 5% (8) of women, and co-infection of HPV18 and the other types was found in 3% (5).

From looking at the viral distribution of HPV between regions (Fig2), it can be seen that 100% of HPV infections in East Xingu were the HR-HPV other-types group. In Middle Xingu, HPV infections included 96.6% (28) of the other-types group (either

alone or co-infected with HPV16) and 6.8% (2 women) with HPV16. In Lower Xingu, the other-types group was represented in 95.5% (42) of infected women and HPV16 in 13.6% (6). Upper Xingu had 88.9% (80) positivity for the other-types group and 12.2% (11) for HPV16 (Table 2).

Regarding the analysis of CT detection, it was observed that 1.8% (18) of women were positive. The distribution analysis by XIP region showed that 38.9% (7) were from Lower Xingu, 27.8% (5) were from Upper Xingu, 22.2% (4) were from Middle Xingu, and 11.1% (2) were from East Xingu (Table 3). Women aged  $\leq 25$  years had a higher frequency of positive tests (55%) than those aged  $\geq 26$  years (45%).

In the CT-positive group, 33% of women had an HPV co-infection (28% had a co-infection with the other-types group and 5% had a co-infection with HPV16 and the other-types group ( $p = 0.083$ )). We did not find any women who were positive for NG.


**Table 1: Human papillomavirus distribution by age group**

HPV detection (n=969)	$\leq 25$ years (n=317) n (%)	$\geq 26$ years (n=652) n (%)	p-value
HPV			
Positive	85 (26.8)	92 (14.1)	<0.0001 <sup>†</sup>
Negative	232 (73.2)	560 (85.9)	
HPV16			
Positive	4 (1.3)	7 (1.1)	0.7562 <sup>†</sup>
Negative	313 (98.7)	645 (98.9)	
HPV18			
Positive	3 (0.9)	5 (0.8)	0.7212 <sup>†</sup>
negative	314 (99.1)	647 (99.2)	
HPV other types			
Positive	72 (22.7)	73 (11.2)	<0.0001 <sup>†</sup>
Negative	245 (77.3)	579 (88.8)	
HPV16 + other types			
Positive	4 (1.3)	4 (0.6)	0.4496 <sup>†</sup>
Negative	313 (98.7)	648 (99.4)	
HPV18 + other types			
Positive	2 (0.6)	3 (0.5)	0.6644 <sup>†</sup>
Negative	315 (99.4)	649 (99.5)	

<sup>†</sup> Pearson's  $\chi^2$  test.

<sup>†</sup> Fisher's exact test.

HPV, human papillomavirus.



HPV, human papillomavirus.

**Figure 2: Location of the Xingu Indigenous Park and frequency of distribution of the high-risk human papillomavirus infections in Indigenous women by region (n=177).**



**Table 2: Distribution of human papillomavirus positivity and viral type by Xingu region**

Region/HPV type	Positive n (%)
Upper Xingu (n=90) (50.8%)	
HPV16	8 (8.9)
HPV18	2 (2.2)
HPV16 + others	3 (3.3)
HPV18 + others	5 (5.6)
Others	72 (80.0)
Lower Xingu (n=44) (24.9%)	
HPV16	2 (4.5)
HPV16 + others	4 (9.1)
Others	38 (86.4)
East Xingu (n=14) (7.9%)	
Others	14 (100)
Middle Xingu (n=29) (16.4%)	
HPV16	1 (3.4)
HPV16 + others	1 (3.4)
HPV18 + others	2 (7)
Others	25 (86.2)

HPV, human papillomavirus.

**Table 3: Distribution of positive cases of *Chlamydia trachomatis* by Xingu region**

Region	Positive n (%)	Negative n (%)
Upper Xingu	5 (27.8)	511 (52.5)
Lower Xingu	7 (38.9)	243 (24.9)
East Xingu	2 (11.1)	78 (8.0)
Middle Xingu	4 (22.2)	142 (14.6)

## Discussion

Although a low proportion of squamous intraepithelial lesions have been reported in the XIP<sup>6,7</sup>, the present study revealed a high incidence of HPV infection (18.2% of women tested were positive). However, fewer than 5% of the infections were HPV16, contrasting with the most frequently reported findings in the literature<sup>29</sup>, which might explain the low frequency of severe cervical lesions reported by others<sup>6,7</sup>.

From these results it can be inferred that the female population studied in the XIP has a specific pattern of HPV frequency, a pattern that is also evident in other populations<sup>30</sup>.

The prevalence of HPV subtypes in Indigenous populations tends to differ from that in the general population<sup>31</sup>. One can speculate whether the pattern of HPV infection in XIP would lead to predictable or unpredictable outcomes regarding neoplastic progression, but there was no evidence to make a credible assumption about the potential association between these types of HR-HPV infections and neoplastic progression. At this point, the most acceptable hypothesis for the findings is a circumstantial laboratorial endpoint and cannot be validated in the present report; however, appropriate study designs in further projects may clarify this speculation.

It could be hypothesized that a factor leading to the relatively higher incidence of types of HPV other than HPV16 or 18 is the quadrivalent HPV vaccine distributed in this population, decreasing the risk of infection by the main types of HR-HPV, 16 and 18, but without ideal coverage for the other HR-HPV types. This suggests the potential added value and usefulness of implementing the nonavalent vaccine in populations with a prevalence of different HPV types. The HPV vaccine has been fully available for young women aged 9–13 years in XIP since 2014, and has substantially reduced the occurrence of severe cervical lesions<sup>32</sup>. The XIP is doing well in this regard, as experienced by well-trained health

professionals who have been visiting the area regularly for many years, with a decrease since the cervical screening program began in the chance of serious cervical abnormalities and their most dire consequences developing. The current data demonstrate that well-organized and uninterrupted prevention minimizes the impacts of oncogenic HPV infection, and that the risks of neoplastic development can be reduced for these Indigenous populations<sup>33</sup>.

Epidemiological statistics related to vaginal infections in Indigenous female populations are not very clear in Brazil, or worldwide<sup>34</sup>. Part of the reason for this lack of information is the difficulties related to geographical access, as the logistics of transit to the places where these populations are located are very limiting. In addition, communication difficulties with the Indigenous women, who remain integrated in their daily lives and cultures in the villages, make interactions problematic, along with the difficulties associated with the provision of medical information and the necessary guidance on the appropriate use of initiatives to control sexually transmissible infectious diseases. This complex network of cultural variables requires careful planning to implement prevention strategies that are adapted to different populations.

The screening processes for cervical cancer in the XIP proposed by the UNIFESP-EPM, based on cytological analysis and clinical examinations, started in 2005 and have had significant results over the years in terms of a reduction in severe cervical lesions. Since then, the coverage rate has reached 90% of sexually active women aged more than 18 years; rates much higher than those found in many metropolitan cities<sup>35,36</sup>. The recommended age for the screening of cervical lesions in Brazil, and in many countries, is 25 years, because at younger ages, there may be a large number of HR-HPV-positive women whose infections will clear up spontaneously, without inducing cervical lesions<sup>15,18</sup>. An arrangement to reduce this age was undertaken by the Xingu Project due to the occurrence of high-grade lesions cases in

women aged less than 25 years. Taking into account that Indigenous women often move to other tribes and have their names changed, it would be very difficult to monitor these patients, as they could avoid the clinical follow-up of serious infections for long periods. In addition, early sexual activity and multiparity are important risk factors for cervical cancer and are very common in XIP<sup>7,37,38</sup>.

As previously mentioned, of the total 992 women who participated in the present study, 18.2% were positive for some type of HR-HPV, and infection by non-HPV16 and non-HPV18 types was evident in 90% of the positive women. Furthermore, women aged ≤25 years were the most affected by non-HPV16 and non-HPV18 types, which was expected due to the early sexual activity in this population. It is worth mentioning that in a previous study conducted by Freitas and colleagues (2016), this population showed a significant prevalence of HPV52 in histological sections of high-grade lesions, which is in agreement with our supposition<sup>39</sup>. When analyzing the viral distribution among the regions, 100% of HPV infections in East Xingu were of non-HPV16 and non-HPV18 types. In Middle Xingu, the same non-HPV16 and non-HPV18 types totaled 96.6% of infections, with 6.8% of infections of HPV16. Of women positive for HPV in Lower Xingu, 95.5% had non-HPV16 and non-HPV18 types and 13.6% had HPV16. In Upper Xingu, the other-types group accounted for 88.9% of HPV infections and HPV16 accounted for 12.2%.

Despite the great success in preventing cervical cancer in the Indigenous people of XIP by NUPREV and the Xingu Project, previous to this present study, there has never been any type of test offered to the women to identify STIs. In the present study, we performed molecular tests for the viral genotyping of HR-HPV, CT, and NG (which are among the main STIs affecting the world), providing for the first time the characteristics of an important epidemiological profile distinguishing these infections in the women of Xingu<sup>12,40</sup>. According to the Centers for Disease Control and Prevention, the screening of CT infections should be started younger than 18 years, ideally at 14–24 years<sup>23</sup>. In the XIP, 1.8% of women were positive for CT. This finding conflicts with that of Ishak and colleagues (2001)<sup>41</sup>. They found 48.6% of immunoglobulin G antibodies to CT in 48 Indigenous communities in the Amazon region. Although comparison of study results for genital infections among American Indigenous women is frequently not feasible because of differences in methodologies, the studies have produced interesting and important data. For example, regarding CT infection, Gabster and colleagues reported a very high prevalence among adolescents in Panama (15.8%)<sup>42</sup>. In another study published by the same authors, a remarkably high prevalence of sexual infections in Indigenous adolescents from Panama was observed, in which bacterial vaginosis and HPV accounted for 42.9% and 33.2%, respectively<sup>43</sup>.

In several studies from around the world, a higher rate of CT infection has been reported in women up to age 25 years<sup>44</sup>, which was also found in XIP. In the present study, we found the highest

CT infection rate in the Lower Xingu region (38.9%), followed by Upper Xingu (27.8%), Middle Xingu (22.2%), and East Xingu (11.1%). No woman was found to be positive for NG, an unexpected fact that warrants further attention. Co-infection of CT and NG is not uncommon, leading us to wonder about the potential implications of the absence of NG in the XIP population<sup>45,46</sup>.

Curiously, 33% of the women positive for CT had co-infections of HPV, all of which were related to non-HPV16 and non-HPV18 types. This index is especially interesting since it has been reported that this co-infection is more frequent in women with high-grade squamous intraepithelial lesion than in those who have only an HR-HPV infection<sup>47</sup>.

Despite the data produced in the present study, it is important to note that understanding of the XIP population would benefit from analysis of a more comprehensive panel of genital infections, and a more inclusive and specific questionnaire on the sexual habits of the women studied (although this would be difficult for cultural reasons). The language barrier was a factor that also limited data collection from the questionnaires, since many different languages and dialects exist in the XIP. Another factor that limited the study development was cost; the study had access to scarce resources and relied on the donation of materials.

## Conclusion

The frequency of HR-HPV was at a high level for a population living in closed Indigenous communities, even though they are close in many ways to communities of other than Indigenous people. We observed a notable frequency of CT and an intriguing absence of NG. Finally, no evidence was found of a potential interrelationship between the three etiologic agents for a combined pathogenic action, also excluding a subsequent synergy between CT infections and HPV. This study provides data on the rates of HPV, CT, and NG in the Indigenous women of Xingu, but it does not examine the relationship between infections with these agents and the development and severity of related diseases.

## Acknowledgements

Thanks to Juliana Galinkas and Vivian Vaz for methodological contributions.

## Statement of funding

This study was financially supported by the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer, Brazil). The Coordination Agency for the Improvement of Higher Education Personnel (CAPES) provided financial assistance during the execution of this project. Abbott Laboratories donated PCR kits for CT and NG; Rovers donated the endocervical brushes. Hospital de Amor, Barretos, Brazil, provided us with the HPV cobas 4800 kits. The Laboratory of Retrovirology in the discipline of Infectology at UNIFESP-EPM provided us with the CT and NG Abbott RealTime tests.

## REFERENCES:

**1** Brazilian Institute of Geography and Statistics. *Database on Indigenous Peoples and Quilombolas. 2019 Indigenous Peoples and Quilombolas*. [In Portuguese]. 2021. Available: [web link](#) (Accessed 30 March 2021).

**2** Brazilian Institute of Geography and Statistics. *Resident population, according to domicile status and indigenous status – Brazil 1991/2010*. [In Portuguese]. 2021. Available: [web link](#) (Accessed 30 March 2021).

- 3** Weis B, Gauditano C, Kahn M, Campanili M. *Social and Environmental Almanac Xingu Indigenous Park: 50 years*. [In Portuguese]. 2011. Available: [web link](#) (Accessed 30 March 2021).
- 4** Lemos PN, Rodrigues DA, Frazão P, Hirooka LB, Guisilini AC, Narvai PC. Oral health care in the Xingu Indigenous Park, Brazil, from 2004 to 2013: an analysis based on evaluation indicators. [In Portuguese]. *Cadernos de Saude Publica* 2018; **34(4)**: e00079317. DOI link
- 5** Ministry of Health of Brazil. *Clinical protocol and therapeutic guidelines for integral care to people with sexually transmitted infections*. [In Portuguese]. 2015. Available: [web link](#) (Accessed 6 April 2021).
- 6** Brito EB, Silva IDC, Stávale JN, Taromaru E, Menezess RC, Martins SJ. Amerindian women of the Brazilian Amazon and STD. *European Journal of Gynaecological Oncology* 2006; **27(3)**: 279-281. PMID:16800259
- 7** Pereira ER, Speck NM, Rodrigues DA, De Freitas VG, Ribalta JCL. Prevention, diagnosis and treatment of cervical cancer precursor lesions at the Xingu Indigenous Park, Brazil. *European Journal of Gynaecological Oncology* 2015; **36(4)**: 376-382. PMID:26390686
- 8** Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. *Journal of Oncology* 2019; **2019**: 3257939. DOI link, PMID:31687023
- 9** Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. *Nature Reviews Cancer* 2010; **10(8)**: 550-560. DOI link, PMID:20592731
- 10** Monsonogo J, Cox JT, Behrens C, Sandri M, Franco EL, Yap P-S, et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. *Gynecologic Oncology* 2015; **137(1)**: 47-54. DOI link, PMID:25667973
- 11** Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2021; **71**: 209-249. DOI link, PMID:33538338
- 12** World Health Organization. *Sexually transmitted infections (STIs)*. 2019. Available: [web link](#) (Accessed 12 August 2021).
- 13** Nonato DR, Alves RRF, Ribeiro AA, Saddi VA, Segati KD, Almeida KP, et al. Prevalence and factors associated with coinfection of human papillomavirus and Chlamydia trachomatis in adolescents and young women. *American Journal of Obstetrics and Gynecology* 2016; **215(6)**: 753.e1-753.e9. DOI link, PMID:27402054
- 14** Robitaille A, Brancaccio RN, Dutta S, Dutta S, Rollison DE, Leja M, et al. PVAmpliconFinder: a workflow for the identification of human papillomaviruses from high-throughput amplicon sequencing. *BMC Bioinformatics* 2020; **21(233)**: 1-18. DOI link, PMID:32513098
- 15** Dockterman J, Coers J. Immunopathogenesis of genital Chlamydia infection: insights from mouse models. *Pathogens and Disease* 2021; **79(4)**: ftab012. DOI link, PMID:33538819
- 16** de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *International Journal of Cancer* 2017; **141(4)**: 664-670. DOI link, PMID:28369882
- 17** Gannon-Loew KE, Holland-Hall C. A review of current guidelines and research on the management of sexually transmitted infections in adolescents and young adults. *Therapeutic Advances in Infectious Disease* 2020; **7**: 2049936120960664. DOI link, PMID:33598210
- 18** World Health Organization, Department of Reproductive Health and Research. *Prevalence and incidence of selected sexually transmitted infections: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates*. World Health Organization, 2011. Available: [web link](#) (Accessed 1 July 2023).
- 19** Cluver C, Novikova N, Eriksson DO, Bengtsson K, Lingman GK. Interventions for treating genital Chlamydia trachomatis infection in pregnancy. *Cochrane Database of Systematic Reviews* 2017; **9(9)**: CD010485. DOI link, PMID:28937705
- 20** BC Center for Disease Control. *STD/AIDS control. Annual report 2003*. 2003. Available: [web link](#) (Accessed 1 July 2023).
- 21** World Health Organization. *Multi-drug resistant gonorrhoea*. World Health Organization, 2020. Available: [web link](#) (Accessed 10 August 2021).
- 22** Graham S, Guy RJ, Donovan B, McManus H, Su J-Y, El-Hayek C, et al. Epidemiology of chlamydia and gonorrhoea among Indigenous and non-Indigenous Australians, 2000-2009. *The Medical Journal of Australia* 2012; **197(11)**: 642-646. DOI link, PMID:23230936
- 23** Centers for Disease Control and Prevention. *National overview – sexually transmitted disease surveillance 2019*. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 2021. Available: [web link](#) (Accessed 28 April 2021).
- 24** Tso FK, Rodrigues CLL, Levi JE, Ferraz MGMC, Speck NMG, Ribalta JCL. HPV infection-associated anogenital cyto-colpo-histological findings and molecular typing in HIV-positive women. *Genetics and Molecular Research* 2015; **14(4)**: 17630-17640. DOI link, PMID:26782408
- 25** Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, et al. Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. *Journal of Clinical Microbiology* 2010; **48(9)**: 3236-3243. DOI link, PMID:20668135
- 26** Cheng A, Qian Q, Kirby JE. Evaluation of the Abbott RealTime CT/NG assay in comparison to the Roche Cobas Amplicor CT/NG assay. *Journal of Clinical Microbiology* 2011; **49(4)**: 1294-1300. DOI link, PMID:21325546
- 27** Adamson PC, Pandori MW, Doernberg SB, Komarow L, Sund Z, Tran TTT, et al. Analytical evaluation of the Abbott RealTime CT/NG assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal swabs. *Journal of Molecular Diagnostics* 2020; **22(6)**: 811-816. DOI link, PMID:32247863
- 28** Han Y, Yin YP, Shi MQ, Zheng BJ, Zhong MY, Jiang N, et al. Evaluation of Abbott RealTime CT/NG assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in cervical swabs from female sex workers in China. *PLoS ONE* 2014; **9(3)**: e89658. DOI link, PMID:24599315
- 29** Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. *JAMA Network Open* 2019; **2(11)**: e1915781. DOI link, PMID:31747033



- 30** Riskey C, Clarke MA, Geisinger KR, Stewart MW, Zhang L, Hoover KW, et al. Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix. *Cancer Cytopathology* 2020; **128(8)**: 528-534. DOI link, PMID:32243726
- 31** Martins TR, De Oliveira CM, Rosa LR, Centrone CC, Rodrigues CLR, Villa LL, et al. HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data. *Virology Journal* 2016; **13**: 138. DOI link, PMID:27515763
- 32** National Cancer Institute, Ministry of Health, Brazil. *Is There a vaccine against HPV?* [In Portuguese]. 2021. Available: [web link](#) (Accessed 12 August 2021).
- 33** Scopin ACC, Cinti CR, Tso FK, Rodrigues D, Longatto Filho A, Munari FF, et al. Impact of cervix uterine cancer screening in the Indian Park of Xingu. *Investigations in Gynecology Research & Womens Health* 2019; **3(2)**: 229-234. DOI link
- 34** Ministry of Health, Brazil. *National Policy for Integral Attention to Women's Health (PNAISM)*. [In Portuguese]. 2004. Available: [web link](#) (Accessed 13 August 2021).
- 35** Speck NMG, Pinheiro JS, Pereira ER, Rodrigues D, Focchi GR, Ribalta JCL. Cervical cancer screening in young and elderly women of the Xingu Indigenous Park: evaluation of the recommended screening age group in Brazil. *Einstein (São Paulo, Brazil)* 2015; **13(1)**: 52-57. DOI link, PMID:25993069
- 36** Speck NMG, Pereira ER, Schaper M, Rodrigues D, Almeida P, Sakano CR, et al. Cytopathological screening in Indigenous women from Parque Indígena do Xingu. *European Journal of Gynaecological Oncology* 2009; **30(5)**: 512-513. PMID:19899404
- 37** Fernandes JV, Meissner VR, de Carvalho MG, Fernandes TA, de Azevedo PR, Villa LL. Prevalence of HPV infection by cervical cytologic status in Brazil. *International Journal of Gynaecology and Obstetrics* 2009; **105(1)**: 21-24. DOI link, PMID:19150057
- 38** Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM. Human papillomavirus and invasive cervical cancer in Brazil. *British Journal of Cancer* 1994; **69(1)**: 114-119. DOI link, PMID:8286192
- 39** Freitas VG, Focchi GR, Pereira ER, Levi JE, Speck NMG, Ribalta JC. HPV genotyping and p16 expression in Xingu Indigenous Park, Brazil. *Genetics and Molecular Research* 2016; **15(3)**: 1-12. DOI link
- 40** Centers for Disease Control and Prevention. *STI Treatment Guidelines*. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 2021. Available: [web link](#) (Accessed 12 July 2021).
- 41** Ishak MO, Ishak R. Chlamydia infection impact among native Indian groups of the Brazilian Amazon region. [In Portuguese]. *Cadernos de Saúde Pública* 2001; **17(2)**: 385-396. DOI link, PMID:11283769
- 42** Gabster A, Mayaud P, Ortiz A, Castillo J, Castellero O, Martínez A, et al. Prevalence and determinants of genital Chlamydia trachomatis among school-going, sexually experienced adolescents in urban and rural Indigenous regions of Panama. *Sexually Transmitted Infections* 2021; **97(4)**: 304-311. DOI link, PMID:32859684
- 43** Gabster A, Pascale JM, Cislighi B, Francis SC, Weiss HA, Martínez A, et al. High prevalence of sexually transmitted infections, and high-risk sexual behaviors among indigenous adolescents of the Comarca Ngäbe-Buglé, Panama. *Sexually Transmitted Diseases* 2019; **46(12)**: 780-787. DOI link, PMID:31596737
- 44** World Health Organization, Department of Reproductive Health and Research. *Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae*. World Health Organization, 2012. Available: [web link](#) (Accessed 30 March 2021).
- 45** Jalil EM, Pinto VM, Benzaken AS, Ribeiro D, Oliveira EC, Garcia EG, et al. Prevalence of Chlamydia and Neisseria gonorrhoeae infections in pregnant women in six Brazilian cities. [In Portuguese]. *Revista Brasileira de Ginecologia e Obstetrícia* 2008; **30(12)**: 614-619. DOI link, PMID:19219343
- 46** Mark KS, Brotman RM, Martinez-Greife S, Terplan M, Bavoil P, Ravel J. Chlamydia in adolescent/adult reproductive management trial study (CHARM): clinical core protocol. *Contemporary Clinical Trials Communications* 2019; **16**: 100414. DOI link, PMID:31646213
- 47** Ji Y, Ma XX, Li Z, Peppelenbosch MP, Ma Z, Pan Q. The burden of human Papillomavirus and Chlamydia trachomatis coinfection in women: a large cohort study in Inner Mongolia, China. *Journal of Infectious Diseases* 2019; **219(2)**: 206-214. DOI link, PMID:30192954